The global Lung Cancer Diagnostic and Screening Market Growth Accelerated by Early Detection Measures
Lung Cancer Diagnostic and Screening Market
Lung cancer is one of the most common and deadly types of cancers,
affecting people's quality of life. Factors such as exposure to secondhand
smoke, genetics, chemicals also contribute to the rise in lung cancer cases.
Early detection through screening and diagnostic tests plays a crucial role in
improving patient outcomes and survival rates. Low-dose Computed Tomography
(LDCT) scans help detect small lung nodules not visible on chest X-rays.
Biomarker tests analyze sputum or blood samples for indications of cancer.
The global Lung Cancer Diagnostic and Screening Market
is estimated to be valued at US$ 2,585.07 Mn in 2024 and is expected to exhibit
a CAGR of 4.1% over the forecast period 2024 to 2031, as highlighted in a new
report published by Coherent Market Insights.
Market Key Trends
The increased emphasis on early detection measures in lung cancer care is one
of the primary drivers fueling the growth of the lung cancer diagnostic and
screening market. Governments and healthcare organizations worldwide are
promoting the use of LDCT screening for high-risk patients through favorable
reimbursement policies and raising awareness. For instance, Medicare, the
national health insurance program for elderly Americans, started covering the cost
of annual LDCT lung cancer screening for eligible older adults. Rising lung
cancer incidence especially in developing nations also creates demand for
advanced diagnostic tools and screening programs for early detection. However,
the high cost associated with LDCT scans, biomarker tests, and other screening
methods remains a key challenge.
Segment Analysis
Global
Lung Cancer Diagnostic And Screening Market Size is dominated by the
non-small cell lung cancer sub-segment. Non-small cell lung cancer accounts for
around 85% of all lung cancer cases. It generally grows and spreads more slowly
than small cell lung cancer. Therefore, non-small cell lung cancer is often
more treatable if it's detected early through screening and diagnosed promptly.
Key Takeaways
The global Lung Cancer Diagnostic and Screening market is expected to witness
high growth. The global Lung Cancer Diagnostic and Screening Market is
estimated to be valued at US$ 2,585.07 Mn in 2024 and is expected to exhibit a
CAGR of 4.1% over the forecast period 2024 to 2031.
Regional analysis shows that North America
currently dominates the market. Factors such as increasing healthcare
expenditure, growing awareness about lung cancer, and rapid technological
advancements in the field of diagnostic and screening are driving market growth
in the region. Asia Pacific is expected to be the fastest growing market during
the forecast period. Rising per capita incomes, growing medical tourism
industry, and expansion of private healthcare systems are some factors
supporting market growth in Asia Pacific.
Key players operating in the Lung Cancer Diagnostic and Screening market are
ExxonMobil, Chevron Phillips Chemical Company, SABIC, China National Petroleum
Corporation (CNPC), BASF. ExxonMobil specializes in innovative diagnostic
imaging technology to detect lung cancer at early stages. Chevron Phillips
Chemical Company offers a wide range of lungs cancer diagnostic tests like CT
imaging, biopsies, bronchoscopy etc to facilitate accurate screening and
diagnosis. SABIC manufactures PET scanners that play a crucial role in lung
cancer staging and chemotherapy response monitoring. China National Petroleum
Corporation (CNPC) provides lung cancer biomarker tests to aid early detection.
BASF develops lung cancer diagnostic kits based on novel bio-markers and
genetic profiling techniques.
Get More Insights on this topic- https://www.newswirestats.com/lung-cancer-diagnostic-and-screening-market-value-future-trends/
Comments
Post a Comment